Advances and Limitations of Antibody Drug Conjugates for Cancer
The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/8/872 |
| _version_ | 1797524676876959744 |
|---|---|
| author | Candice Maria Mckertish Veysel Kayser |
| author_facet | Candice Maria Mckertish Veysel Kayser |
| author_sort | Candice Maria Mckertish |
| collection | DOAJ |
| description | The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The current research focuses on overcoming intrinsic shortcomings that impact the successful development of ADCs. This review summarizes marketed and recently approved ADCs, compares the features of various linker designs and payloads commonly used for ADC conjugation, and outlines cancer specific ADCs that are currently in late-stage clinical trials for the treatment of cancer. In addition, it addresses the issues surrounding drug resistance and strategies to overcome resistance, the impact of a narrow therapeutic index on treatment outcomes, the impact of drug–antibody ratio (DAR) and hydrophobicity on ADC clearance and protein aggregation. |
| first_indexed | 2024-03-10T08:59:54Z |
| format | Article |
| id | doaj.art-ea8f9ccae8f84009840cf6f2c264b11a |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T08:59:54Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-ea8f9ccae8f84009840cf6f2c264b11a2023-11-22T06:51:19ZengMDPI AGBiomedicines2227-90592021-07-019887210.3390/biomedicines9080872Advances and Limitations of Antibody Drug Conjugates for CancerCandice Maria Mckertish0Veysel Kayser1Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, AustraliaSydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, AustraliaThe popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The current research focuses on overcoming intrinsic shortcomings that impact the successful development of ADCs. This review summarizes marketed and recently approved ADCs, compares the features of various linker designs and payloads commonly used for ADC conjugation, and outlines cancer specific ADCs that are currently in late-stage clinical trials for the treatment of cancer. In addition, it addresses the issues surrounding drug resistance and strategies to overcome resistance, the impact of a narrow therapeutic index on treatment outcomes, the impact of drug–antibody ratio (DAR) and hydrophobicity on ADC clearance and protein aggregation.https://www.mdpi.com/2227-9059/9/8/872antibody drug conjugatesdrug resistancelinkerspayloadstherapeutic indextarget specific |
| spellingShingle | Candice Maria Mckertish Veysel Kayser Advances and Limitations of Antibody Drug Conjugates for Cancer Biomedicines antibody drug conjugates drug resistance linkers payloads therapeutic index target specific |
| title | Advances and Limitations of Antibody Drug Conjugates for Cancer |
| title_full | Advances and Limitations of Antibody Drug Conjugates for Cancer |
| title_fullStr | Advances and Limitations of Antibody Drug Conjugates for Cancer |
| title_full_unstemmed | Advances and Limitations of Antibody Drug Conjugates for Cancer |
| title_short | Advances and Limitations of Antibody Drug Conjugates for Cancer |
| title_sort | advances and limitations of antibody drug conjugates for cancer |
| topic | antibody drug conjugates drug resistance linkers payloads therapeutic index target specific |
| url | https://www.mdpi.com/2227-9059/9/8/872 |
| work_keys_str_mv | AT candicemariamckertish advancesandlimitationsofantibodydrugconjugatesforcancer AT veyselkayser advancesandlimitationsofantibodydrugconjugatesforcancer |